Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Cytostatic Therapy | Research

Cost-effectiveness of first-line immunotherapy combinations with or without chemotherapy for advanced non–small cell lung cancer: a modelling approach

Authors: Wen Hui, Ruomeng Song, Hongyu Tao, Zhixiang Gao, Min Zhu, Mingyue Zhang, Huazhang Wu, Daichen Gong, Xiyan Zhang, Yuanyi Cai

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

Many studies have explored the cost-effectiveness of immunotherapy versus chemotherapy alone. However, there is paucity of evidence on direct pharmacoeconomic studies related to immunotherapy combinations. Thus, we aimed at assessing the economic outcomes of first-line immunotherapy combinations in the treatment of advanced non-small cell lung cancer (NSCLC) from the Chinese health care perspective.

Methods

The mutual hazard ratios (HRs) of ten immunotherapy combinations and one chemotherapy regimen for the overall survival (OS) and progression-free survival (PFS) were obtained from a network meta-analysis. Based on proportional hazard (PH) assumption, adjusted OS and PFS curves were established to make the effects comparable. With the parameters of cost and utility, and of scale and shape from the fit of adjusted OS and PFS curves obtained from previous studies, a partitioned survival model was designed to estimate the cost-effectiveness of immunotherapy combinations versus chemotherapy alone. Parameter uncertainty in model inputs was assessed using one-way deterministic and probabilistic sensitivity analyses.

Results

The incremental cost of camrelizumab plus chemotherapy versus chemotherapy alone was $13,180.65, the lowest among all the other immunotherapy combinations. Furthermore, sintilimab plus chemotherapy (sint-chemo) provided the highest quality-adjusted life-year (QALY) benefit versus chemotherapy alone (incremental QALYs = 0.45). Sint-chemo yielded the best incremental cost-effectiveness ratio (ICER) versus chemotherapy alone (ICER = $34,912.09/QALY), at the current price. The cost-effectiveness probabilities were 32.01% and 93.91% for pembrolizumab plus chemotherapy, and atezolizumab plus bevacizumab plus chemotherapy, respectively (if the original price of the pembrolizumab, atezolizumab, and bevacizumab were decreased by 90%).

Conclusions

Based on the fact that there is fierce competition in the PD-1/PD-L1 market, pharmaceutical enterprises should strive for greater efficacy, and optimal pricing strategy for therapies.
Appendix
Available only for authorised users
Literature
1.
Mao YS, Yang D, He J, Krasna MJ. Epidemiology of Lung Cancer. Surg Oncol Clin N Am. 2016;25(3):439–45.PubMedCrossRef
2.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49.PubMedCrossRef
3.
Wu B, Gu XH, Zhang Q. Cost-Effectiveness of Osimertinib for EGFR Mutation- Positive Non-Small Cell Lung Cancer after Progression Following First-Line EGFR TKI Therapy. J Thorac Oncol. 2018;13(2):184–93.PubMedCrossRef
4.
Royal College of Physicians. National Lung Cancer Audit annual report 2016 (for the audit period 2015). London: Royal College of Physicians; 2017.
5.
6.
Fan H, Shao ZY, Xiao YY, Xie ZH, Chen W, Xie H, et al. Incidence and Survival of Non-Small Cell Lung Cancer in Shanghai: A Population-Based Cohort Study. BMJ Open. 2015;5(12):e009419.PubMedPubMedCentralCrossRef
7.
Gadgeel S, Rodrı́guez-Abreu D, Speranza G, Esteban E, Felip E, Dómine M, et al. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2020;38(14):1505–17.PubMedCrossRef
8.
Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, et al. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288–301.PubMedCrossRef
9.
Reck M, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, et al. First-Line Nivolumab plus Ipilimumab with Two Cycles of Chemotherapy versus Chemotherapy Alone (four cycles) in Advanced Non-Small-Cell Lung Cancer: CheckMate 9LA 2-year update. ESMO Open. 2021;6(5):1–13.CrossRef
10.
Rizvi NA, Cho BC, Reinmuth N, Lee KH, Luft A, Ahn MJ, et al. Durvalumab with or without Tremelimumab vs Standard Chemotherapy in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer: the MYSTIC Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020;6(5):661–74.PubMedPubMedCentralCrossRef
11.
Early Breast Cancer Trialists’ Collaborative group (EBCTCG). Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. Lancet Oncol. 2021;22(8):1139–50.CrossRef
12.
Conforti F, Pala L, Sala I, Oriecuia C, De Pas T, Specchia C, et al. Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis. BMJ. 2021;375:e066381.PubMedPubMedCentralCrossRef
13.
Zhang W, Huang ZK, Zhang JW, Che X. Long-term and short-term outcomes after laparoscopic versus open surgery for advanced gastric cancer: An updated meta-analysis. J Minim Access Surg. 2021;17(4):423–34.PubMedPubMedCentralCrossRef
14.
Wang HY, Liu YH, Shen KJ, Dong YX, Sun JY, Shu YM, et al. A comparison between radiofrequency ablation combined with transarterial chemoembolization and surgical resection in hepatic carcinoma: A meta-analysis. J Cancer Res Ther. 2019;15(7):1617–23.PubMedCrossRef
15.
Wang HY, Cao C, Wei XY, Shen KJ, Shu YM, Wan XJ, et al. A comparison between drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis of six randomized controlled trials. J Cancer Res Ther. 2020;16(2):243–9.PubMedCrossRef
16.
Ferrara R, Imbimbo M, Malouf R, Paget-Bailly S, Calais F, Marchal C, et al. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. Cochrane Database Syst Rev. 2021;4(4):CD013257.PubMed
17.
He MF, Zheng TH, Zhang XY, Peng Y, Jiang X, Huang YS, et al. First-line treatment options for advanced non-small cell lung cancer patients with PD-L1 ≥ 50%: a systematic review and network meta-analysis. Cancer Immunol Immunother. 2022;71(6):1345–55.PubMedCrossRef
18.
Dafni U, Tsourti Z, Vervita K, Peters S. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer A systematic review and network meta-analysis. Lung Cancer. 2019;134:127–40.PubMedCrossRef
19.
Liu Q, Zhou Z, Luo X, Yi LD, Peng LB, Wan XM, et al. First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis. Front Pharmacol. 2021;12:788569.PubMedPubMedCentralCrossRef
20.
Kang S, Wang XC, Zhang Y, Zhang BY, Shang FJ, Guo W. First-Line Treatments for Extensive-Stage Small-Cell Lung Cancer With Immune Checkpoint Inhibitors Plus Chemotherapy: A Network Meta-Analysis and Cost-Effectiveness Analysis. Front Oncol. 2022;11:1–11.CrossRef
21.
Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force. Value Health. 2022;25(1):10–31.PubMedCrossRef
22.
Liu LH, Bai H, Wang C, Seery S, Wang ZJ, Duan JC, et al. Efficacy and Safety of First-Line Immunotherapy Combinations for Advanced NSCLC: A Systematic Review and Network Meta-Analysis. J Thorac Oncol. 2021;16(7):1099–117.PubMedCrossRef
23.
West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, et al. Atezolizumab in Combination with Carboplatin plus Nab-Paclitaxel Chemotherapy Compared with Chemotherapy Alone as First-Line Treatment for Metastatic Non-Squamous Non-Small-Cell Lung Cancer (IMpower130): A Multicentre, Randomised, Open-Label, Phase 3 Trial. Lancet Oncol. 2019;20(7):924–37.PubMedCrossRef
24.
Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced Secondary Analysis of Survival Data: Reconstructing the Data from Published Kaplan-Meier Survival Curves. BMC Med Res Methodol. 2012;12:9.PubMedPubMedCentralCrossRef
25.
Liu GE, Hu SL, Wu JH, Wu J, Dong ZH, Li HC, et al. China Guidelines for Pharmacoeconomic Evaluations (2020 Version). Beijing: China Market Press; 2020. p. 27.
26.
27.
Xu H, Ma AX. Cost-Effectiveness Analysis of Pembrolizumab versus Chemotherapy as First-Line Treatment in Non-Small Cell Lung Cancer With Different PD-L1 Expression Levels Based on Partitioned Survival Model. Chin J Hosp Pharm. 2020;40:1–8.
28.
Gao HT, Hu MX, Jia LL, Wu F, Hou YH. Cost- Utility Analysis of Sintilimab Combined with Chemotherapy in First- Line Treatment of Advanced or Recurrent Non-Small Cell Lung Cancer. China Pharmacy. 2022;33(15):1854–9.
29.
Zhou CC, Chen GY, Huang YC, Zhou JY, Lin LZ, Feng JF, et al. Camrelizumab plus Carboplatin and Pemetrexed versus Chemotherapy Alone in Chemotherapy-Naive Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer (CameL): A Randomised, Open Label, Multicentre, Phase 3 Trial. Lancet Respir Med. 2021;9(3):305–14.PubMedCrossRef
30.
31.
32.
33.
Xu H, Ma AX. Cost-Effectiveness Analysis of Pembrolizumab versus Chemotherapy as First-Line Treatment in Non-Small Cell Lung Cancer in China Based on Markov Model. Chin J Mod Appl Pharm. 2021;38(4):473–9.
34.
Chinese Association for Clinical Oncologists and Medical Oncology Branch of Chinese International Exchange and Promotion Association for Medical and Healthcare. Clinical Practice Guideline for Stage IV Primary Lung Cancer in China (2021 Version). Chin J Oncol. 2021;43(1):39–59.
35.
Nafees B, Lloyd AJ, Dewilde S, Rajan N, Lorenzo M. Health State Utilities in Non-Small Cell Lung Cancer: An International Study. Asia Pac J Clin Oncol. 2017;13:e195–203.PubMedCrossRef
36.
Borghaei H, Langer CJ, Gadgeel S, Papadimitrakopoulou VA, Patnaik A, Powell SF, et al. 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer. J Thorac Oncol. 2019;14(1):124–9.PubMedCrossRef
37.
Paz-Ares L, Vicente D, Tafreshi A, Robinson A, Parra HS, Mazières J, et al. A Randomized, Placebo-Controlled Trial of Pembrolizumab plus Chemotherapy in Patients with Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407. J Thorac Oncol. 2020;15(10):1657–69.PubMedCrossRef
38.
Jotte R, Cappuzzo F, Vynnychenko I, Stroyakovskiy D, Rodríguez-Abreu D, Hussein M, et al. Atezolizumab in Combination with Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results from A Randomized Phase III Trial. J Thorac Oncol. 2020;15(8):1351–60.PubMedCrossRef
39.
Nishio M, Barlesi F, West H, Ball S, Bordoni R, Cobo M, et al. Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial. J Thorac Oncol. 2021;16(4):653–64.PubMedCrossRef
40.
Paz-Ares LG, Ramalingam SS, Ciuleanu TE, Lee JS, Urban L, Caro RB, et al. First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial. J Thorac Oncol. 2022;17(2):289–308.PubMedCrossRef
41.
Leighl NB, Laurie SA, Goss GD, Hughes BGM, Stockler M, Tsao MS, et al. CCTG BR34: A Randomized Phase 2 Trial of Durvalumab and Tremelimumab With or Without Platinum-Based Chemotherapy in Patients with Metastatic NSCLC. J Thorac Oncol. 2022;17(3):434–45.PubMedCrossRef
42.
Lu S, Wang J, Yu Y, Yu XM, Hu YP, Ai XH, et al. Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial. J Thorac Oncol. 2021;16(9):1512–22.PubMedCrossRef
43.
Wang J, Lu S, Yu XM, Hu YP, Sun YP, Wang ZJ, et al. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021;7(5):709–17.PubMedPubMedCentralCrossRef
44.
Yang YP, Wang ZH, Fang J, Yu QT, Han BH, Cang SD, et al. Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11). J Thorac Oncol. 2020;15(10):1636–46.PubMedCrossRef
45.
Zhou CC, Wu L, Fan Y, Wang ZH, Liu LK, Chen GY, et al. Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12). J Thorac Oncol. 2021;16(9):1501–11.PubMedCrossRef
46.
Reck M, Remon J, Hellmann MD. First-Line Immunotherapy for Non-Small-Cell Lung Cancer. J Clin Oncol. 2022;40(6):586–97.PubMedCrossRef
47.
Wu B, Zhang Q, Sun J. Cost-Effectiveness of Nivolumab Plus Ipilimumab as First-Line Therapy in Advanced Renal-Cell Carcinoma. J Immunother Cancer. 2018;6(1):124.PubMedPubMedCentralCrossRef
48.
Briggs AH, Weinstein MC, Fenwick EAL, Karnon J, Sculpher MJ, Paltiel AD, et al. Model Parameter Estimation and Uncertainty Analysis: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6. Med Decis Making. 2012;32(5):722–32.PubMedCrossRef
49.
Hao XZ, Shen AZ, Wu B. Cost-Effectiveness of Nivolumab Plus Ipilimumab as First-Line Therapy in Advanced Non-small-cell Lung Cancer. Front Pharmacol. 2021;12:573852.PubMedPubMedCentralCrossRef
50.
Hu HB, She LJ, Liao MT, Shi Y, Yao LL, Ding D, et al. Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab vs Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer. Front Oncol. 2020;10:1649.PubMedPubMedCentralCrossRef
51.
Jiang Y, Wang XW. Cost-effectiveness Analysis of Pembrolizumab Plus Standard Chemotherapy Versus Chemotherapy Alone for First-Line Treatment of Metastatic Non-Squamous Non-Small-Cell Lung Cancer in China. Eur J Hosp Pharm. 2022;29(3):139–44.PubMedCrossRef
52.
Criss SD, Mooradian MJ, Watson TR, Gainor JF, Reynolds KL, Kong CY. Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer in the United States. JAMA Netw Open. 2019;2(9):e1911952.PubMedPubMedCentralCrossRef
53.
Ding D, Hu HB, Liao MT, Shi Y, She LJ, Yao LL, et al. Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer. Adv Ther. 2020;37(5):2116–26.PubMedCrossRef
54.
Yang ZG, Zhu YM, Xiang GY, Hua TT, Ni J, Zhao J, et al. First-Line Atezolizumab Plus Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer: A Cost-Effectiveness Analysis from China. Expert Rev Pharmacoecon Outcomes Res. 2021;21(5):1061–7.PubMedCrossRef
55.
56.
Jansen JP, Fleurence R, Devine B, Itzler R, Barrett A, Hawkins N, et al. Interpreting Indirect Treatment Comparisons and Network Meta-Analysis for Health-Care Decision Making: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1. Value Health. 2011;14(4):417–28.PubMedCrossRef
57.
Bucher HC, Guyatt GH, Griffith LE, Walter SD. The Results of Direct and Indirect Treatment Comparisons in Meta-Analysis of Randomized Controlled Trials. J Clin Epidemiol. 1997;50(6):683–91.PubMedCrossRef
58.
Gartlehner G, Moore CG. Direct Versus Indirect Comparisons: A Summary of the Evidence. Int J Technol Assess Health Care. 2008;24(2):170–7.PubMedCrossRef
59.
Lim E, Ali Z, Ali A, Routledge T, Edmonds L, Altman DG, et al. Indirect Comparison Meta-Analysis of Aspirin Therapy after Coronary Surgery. BMJ. 2003;327(7427):1309.PubMedPubMedCentralCrossRef
Metadata
Title
Cost-effectiveness of first-line immunotherapy combinations with or without chemotherapy for advanced non–small cell lung cancer: a modelling approach
Authors
Wen Hui
Ruomeng Song
Hongyu Tao
Zhixiang Gao
Min Zhu
Mingyue Zhang
Huazhang Wu
Daichen Gong
Xiyan Zhang
Yuanyi Cai
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-10938-8

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue

Research

MMP14 expression levels accurately predict the presence of extranodal extensions in oral squamous cell carcinoma: a retrospective cohort study

Research

The effect of sarcopenia and sarcopenic obesity on survival in gastric cancer

Research

Efficacy and safety of mirogabalin for chemotherapy-induced peripheral neuropathy: a prospective single-arm trial (MiroCIP study)

Research

“What I wanted to do was build myself back up and prepare”: qualitative findings from the PERCEPT trial of prehabilitation during autologous stem cell transplantation in myeloma

Study Protocol

Radiotherapy versus low-dose tamoxifen following breast-conserving surgery for low-risk and estrogen receptor-positive breast ductal carcinoma in situ: an international open-label randomized non-inferiority trial (TBCC-ARO DCIS Trial)

Research

Assessing awareness of blood cancer symptoms and barriers to symptomatic presentation: measure development and results from a population survey in the UK
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits